Hematological toxicity of adjuvant portal liver infusion with fluorouracil, mitomycin and heparin.
Adjuvant perioperative liver infusion chemotherapy with fluorouracil, mitomycin and heparin caused mild but significant myelosuppression in the first two postoperative weeks. This was associated with a slightly increased bleeding tendency. Mortality was not increased. Future trials might combine chemotherapy with hematopoietic growth factors in order to minimize myelosuppression.
Weber
W
W
Group for Epidemiologic and Clinical Cancer Research (SAKK), Berne, Switzerland.
Metzger
U
U
Laffer
U
U
Egeli
R
R
D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use / Q000633:toxicity*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000633:toxicity; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000187:drug effects; D006493:Heparin / Q000008:administration & dosage* / Q000633:toxicity; D006801:Humans; D007262:Infusions, Intravenous; D007958:Leukocyte Count / Q000187:drug effects*; D008297:Male; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage* / Q000633:toxicity; D010976:Platelet Count / Q000187:drug effects*; D011169:Portal Vein; D011897:Random Allocation; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
D000970:Antineoplastic Agents; D006454:Hemoglobins; D008937:Mitomycins; D016685:Mitomycin; D006493:Heparin; D005472:Fluorouracil